Published in Carcinogenesis on October 04, 2007
Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene (2009) 2.32
Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A (2012) 1.66
Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med (2012) 1.61
Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway. Leuk Res (2013) 1.60
Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40
The transcription factor p53: not a repressor, solely an activator. Cell Cycle (2014) 1.23
RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget (2015) 1.20
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer (2011) 1.18
Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer (2010) 1.17
One function--multiple mechanisms: the manifold activities of p53 as a transcriptional repressor. J Biomed Biotechnol (2011) 1.14
The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene (2010) 1.12
Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One (2011) 1.11
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer (2009) 1.01
A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells. PLoS One (2012) 1.00
Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex. Oncotarget (2015) 0.98
Insulin Protects Cardiac Myocytes from Doxorubicin Toxicity by Sp1-Mediated Transactivation of Survivin. PLoS One (2015) 0.83
Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions. J Invest Dermatol (2012) 0.83
The impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment. Aging Cell (2013) 0.82
Depletion of K-Ras promotes proteasome degradation of survivin. Cell Cycle (2013) 0.82
Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. J Biol Chem (2014) 0.82
Differential proteomics analysis reveals a role for E2F2 in the regulation of the Ahr pathway in T lymphocytes. Mol Cell Proteomics (2010) 0.78
Census and evaluation of p53 target genes. Oncogene (2017) 0.77
1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cells. Int J Oncol (2009) 0.77
Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells. Oxid Med Cell Longev (2014) 0.77
Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation. Oncotarget (2015) 0.77
Yin Yang 1 regulates the transcriptional repression of Survivin. Biochem Biophys Res Commun (2014) 0.76
Epithelial PIK3R1 (p85) and TP53 Regulate Survivin Expression during Adaptation to Ileocecal Resection. Am J Pathol (2016) 0.75
Dihydromyricetin Induces Apoptosis and Reverses Drug Resistance in Ovarian Cancer Cells by p53-mediated Downregulation of Survivin. Sci Rep (2017) 0.75
Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas. Med Sci Monit (2011) 0.75
Epithelial TNF Receptor Signaling Promotes Mucosal Repair in Inflammatory Bowel Disease. J Immunol (2017) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Melanoma. N Engl J Med (2006) 8.80
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol (2002) 7.64
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene (2003) 4.52
Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem (2001) 4.21
SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene (2005) 3.77
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell (2003) 3.23
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene (2002) 3.12
Chromosome alignment and segregation regulated by ubiquitination of survivin. Science (2005) 3.09
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res (2003) 2.72
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Pathways governing G1/S transition and their response to DNA damage. FEBS Lett (2001) 2.58
p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem (2003) 2.43
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer (2003) 2.28
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol (1999) 2.21
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A (2006) 2.10
Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity (2001) 2.09
The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci (2000) 1.93
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet (2005) 1.90
Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A (2001) 1.89
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem (2006) 1.83
Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res (2003) 1.83
Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol (2003) 1.73
A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet (2001) 1.70
Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc Natl Acad Sci U S A (2005) 1.67
Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem (2004) 1.58
The INK4a/ARF locus and melanoma. Oncogene (2003) 1.57
Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol (2003) 1.39
KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem (2006) 1.30
Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem (2005) 1.27
The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology (2006) 1.25
Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res (1994) 1.24
A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol (2004) 1.24
The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene (2006) 1.22
Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol (2006) 1.13
Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res (2006) 1.13
DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett (2001) 1.12
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res (1996) 1.10
Rb/E2F: a two-edged sword in the melanocytic system. Cancer Metastasis Rev (2005) 1.06
Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem (2006) 1.05
Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer (2005) 1.03
Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene (2006) 0.95
Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dermatol (2004) 0.90
No longer a molecular black box--new clues to apoptosis and drug resistance in melanoma. Trends Mol Med (2001) 0.83
Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med (2010) 4.23
Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature (2012) 3.83
Human MIEF1 recruits Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than fission. EMBO J (2011) 2.71
A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell (2008) 2.47
Conformational changes in the G protein Gs induced by the β2 adrenergic receptor. Nature (2011) 2.43
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28
Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol (2007) 2.11
Structural flexibility of the G alpha s alpha-helical domain in the beta2-adrenoceptor Gs complex. Proc Natl Acad Sci U S A (2011) 2.03
Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat Med (2013) 1.93
Genomic analysis of the immune gene repertoire of amphioxus reveals extraordinary innate complexity and diversity. Genome Res (2008) 1.92
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem (2004) 1.73
Resolving TRPV1- and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci (2011) 1.58
Adaptation of cardiac action potential durations to stimulation history with random diastolic intervals. J Cardiovasc Electrophysiol (2004) 1.53
Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer (2008) 1.52
Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A (2011) 1.51
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol (2004) 1.50
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene (2004) 1.49
Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Dermatol Surg (2010) 1.46
Structure-function analysis of Frizzleds. Cell Signal (2006) 1.45
Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg (2012) 1.42
Spontaneously alternating forms of the atrioventricular node reentrant tachycardia. Pacing Clin Electrophysiol (2011) 1.42
Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res (2007) 1.42
Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol (2003) 1.39
Two-dimensional speckle tracking echocardiography: a novel approach to evaluate left atrial mechanical function. Int J Cardiol (2012) 1.38
Optimized proteomic analysis of a mouse model of cerebellar dysfunction using amine-specific isobaric tags. Proteomics (2006) 1.37
Quantitative analysis of redox-sensitive proteome with DIGE and ICAT. J Proteome Res (2008) 1.37
Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol (2011) 1.36
Roles for the human ATP-dependent Lon protease in mitochondrial DNA maintenance. J Biol Chem (2007) 1.34
Mechanism of intracellular cAMP sensor Epac2 activation: cAMP-induced conformational changes identified by amide hydrogen/deuterium exchange mass spectrometry (DXMS). J Biol Chem (2011) 1.32
TNF-α contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain (2010) 1.31
Molecular mimicry in innate immunity: crystal structure of a bacterial TIR domain. J Biol Chem (2009) 1.29
Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol (2006) 1.28
Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J Neurosci (2011) 1.27
Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem (2005) 1.27
Isoform-specific antagonists of exchange proteins directly activated by cAMP. Proc Natl Acad Sci U S A (2012) 1.27
Cell-surface prion protein interacts with glycosaminoglycans. Biochem J (2002) 1.27
VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res (2006) 1.26
Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res (2003) 1.26
DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther (2002) 1.26
Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med (2010) 1.24
Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl Trop Dis (2011) 1.23
Redox regulatory mechanism of transnitrosylation by thioredoxin. Mol Cell Proteomics (2010) 1.23
Autonomic nerve stimulation reverses ventricular repolarization sequence in rabbit hearts. Circ Res (2007) 1.22
Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques (2004) 1.21
Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol (2003) 1.20
The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog (2012) 1.20
Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat (2006) 1.20
Heterogeneity of normal prion protein in two- dimensional immunoblot: presence of various glycosylated and truncated forms. J Neurochem (2002) 1.18
Electrophysiological characteristics of focal atrial tachycardia surrounding the aortic coronary cusps. Circ Arrhythm Electrophysiol (2011) 1.18
Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry (2004) 1.17
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol (2006) 1.17
Cleavage site selection within a folded substrate by the ATP-dependent lon protease. J Biol Chem (2005) 1.16
Life span of ventricular fibrillation frequencies. Circ Res (2002) 1.16
Structural basis for differential neutralization of ebolaviruses. Viruses (2012) 1.15
The role of protein conformational fluctuations in allostery, function, and evolution. Biophys Chem (2011) 1.15
UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis (2004) 1.13
Understanding resistant germplasm-induced virulence variation through analysis of proteomics and suppression subtractive hybridization in a maize pathogen Curvularia lunata. Proteomics (2012) 1.13
Induction of cell cycle arrest by human T-cell lymphotropic virus type 1 Tax in hematopoietic progenitor (CD34+) cells: modulation of p21cip1/waf1 and p27kip1 expression. J Virol (2005) 1.13
Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-α secretion. J Clin Invest (2014) 1.12
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Biochemical characterization of Trypanosoma brucei RNA polymerase II. Mol Biochem Parasitol (2006) 1.11
Elucidation of thioredoxin target protein networks in mouse. Mol Cell Proteomics (2009) 1.11
Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer (2005) 1.10
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
A strategy for direct identification of protein S-nitrosylation sites by quadrupole time-of-flight mass spectrometry. J Am Soc Mass Spectrom (2008) 1.09
Loss of NR1 subunit of NMDARs in primary sensory neurons leads to hyperexcitability and pain hypersensitivity: involvement of Ca(2+)-activated small conductance potassium channels. J Neurosci (2013) 1.09
The ATP-dependent Lon protease of Mus musculus is a DNA-binding protein that is functionally conserved between yeast and mammals. Gene (2003) 1.08
Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol (2012) 1.08
Plasticity of cytochrome P450 2B4 as investigated by hydrogen-deuterium exchange mass spectrometry and X-ray crystallography. J Biol Chem (2010) 1.08
Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res (2010) 1.07
Receptor for advanced glycation end products (RAGE): novel biomarker and therapeutic target for atrial fibrillation. Int J Cardiol (2013) 1.07
Structural basis of M3 muscarinic receptor dimer/oligomer formation. J Biol Chem (2011) 1.06
Anticoagulant-Related Nephropathy. J Am Coll Cardiol (2015) 1.06
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate (2011) 1.06
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One (2012) 1.05
A Drosophila DEG/ENaC subunit functions specifically in gustatory neurons required for male courtship behavior. J Neurosci (2012) 1.05
Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity. Biochemistry (2011) 1.05
Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry (2005) 1.04
The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther (2006) 1.04
Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res (2012) 1.03
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol (2009) 1.03
An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene (2004) 1.02
Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry (2006) 1.02
Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem (2007) 1.01
Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. J Med Chem (2011) 1.00
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res (2003) 1.00
Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry (2005) 0.99
N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res (2007) 0.98
Distinction of thioredoxin transnitrosylation and denitrosylation target proteins by the ICAT quantitative approach. J Proteomics (2011) 0.98
Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. PLoS One (2013) 0.98
Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy. Clin Cancer Res (2008) 0.97
Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem (2007) 0.97
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther (2008) 0.97
Thioredoxin 1-mediated post-translational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies. Antioxid Redox Signal (2011) 0.97